Diffusion-Weighted Imaging of the Male Pelvis

Radiologic Clinics of North America

Volumn 50, Issue 6, 2012, Pages 1127-1144

  Koh, Dow Mu ^a   Sohaib, Aslam ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Diffusion weighted MR imaging; Male pelvis; MR imaging; Pelvic malignancies

Indexed keywords

ANTINEOPLASTIC AGENT;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; HUMAN; IMAGE ANALYSIS; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PELVIS CANCER; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; PELVIS; PROSTATE; PROSTATIC NEOPLASMS; RECTAL NEOPLASMS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84868285679     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2012.08.008     Document Type: Review

References (110)

1. Koh D.M., Collins D.J. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007, 188(6):1622-1635.
2. Koh D.M., Takahara T., Imai Y., et al. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci 2007, 6(4):211-224.
3. Kitajima K., Takahashi S., Ueno Y., et al. Clinical utility of apparent diffusion coefficient values obtained using high b-value when diagnosing prostate cancer using 3 tesla MRI: comparison between ultra-high b-value (2000 s/mm(2)) and standard high b-value (1000 s/mm(2)). J Magn Reson Imaging 2012, 36(1):198-205.
4. Kitajima K., Kaji Y., Kuroda K., et al. High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of the prostate: effect of signal-to-noise ratio. Magn Reson Med Sci 2008, 7(2):93-99.
5. Katahira K., Takahara T., Kwee T.C., et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol 2011, 21(1):188-196.
6. Ahmed H.U. The index lesion and the origin of prostate cancer. N Engl J Med 2009, 361(17):1704-1706.
7. Dall'Era M.A., Cooperberg M.R., Chan J.M., et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008, 112(8):1650-1659.
8. Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why?. Nat Clin Pract Oncol 2007, 4(12):692-698.
9. Parker C. Active surveillance of early prostate cancer: rationale, initial results and future developments. Prostate Cancer Prostatic Dis 2004, 7(3):184-187.
10. Williams S.B., Lei Y., Nguyen P.L., et al. Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer. BJU Int 2012, 110(2 Pt B):E92-E98.
11. Ward J.F., Jones J.S. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 2012, 109(11):1648-1654.
12. Vargas H.A., Akin O., Franiel T., et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011, 259(3):775-784.
13. Yagci A.B., Ozari N., Aybek Z., et al. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn Interv Radiol 2011, 17(2):130-134.
14. Lim H.K., Kim J.K., Kim K.A., et al. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection: a multireader study. Radiology 2009, 250(1):145-151.
15. Haider M.A., van der Kwast T.H., Tanguay J., et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007, 189(2):323-328.
16. Morgan V.A., Kyriazi S., Ashley S.E., et al. Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection. Acta Radiol 2007, 48(6):695-703.
17. Miao H., Fukatsu H., Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 2007, 61(2):297-302.
18. Doo K.W., Sung D.J., Park B.J., et al. Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol 2012, 22(8):1812-1819.
19. Rosenkrantz A.B., Mannelli L., Kong X., et al. Prostate cancer: utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization. J Magn Reson Imaging 2011, 34(1):95-100.
20. Delongchamps N.B., Rouanne M., Flam T., et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int 2011, 107(9):1411-1418.
21. Hatano K., Tsuda K., Kawamura N., et al. Nihon Hinyokika Gakkai Zasshi 2010, 101(4):603-608. [in Japanese].
22. Yoshimitsu K., Kiyoshima K., Irie H., et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 2008, 27(1):132-139.
23. Roy C., Pasquali R., Matau A., et al. J Radiol 2010, 91(11 Pt 1):1121-1128. [in French].
24. Park B.K., Lee H.M., Kim C.K., et al. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol 2008, 43(11):789-793.
25. Chen Y.J., Pu Y.S., Chueh S.C., et al. Diffusion MRI predicts transrectal ultrasound biopsy results in prostate cancer detection. J Magn Reson Imaging 2011, 33(2):356-363.
26. Kumar V., Jagannathan N.R., Kumar R., et al. Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR Biomed 2007, 20(5):505-511.
27. Ren J., Huan Y., Li F., et al. Combined T2-weighted and diffusion-weighted MRI for diagnosis of urinary bladder invasion in patients with prostate carcinoma. J Magn Reson Imaging 2009, 30(2):351-356.
28. Ren J., Huan Y., Wang H., et al. Seminal vesicle invasion in prostate cancer: prediction with combined T2-weighted and diffusion-weighted MR imaging. Eur Radiol 2009, 19(10):2481-2486.
29. Chen M., Dang H.D., Wang J.Y., et al. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 2008, 49(5):602-610.
30. deSouza N.M., Reinsberg S.A., Scurr E.D., et al. Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol 2007, 80(950):90-95.
31. Jeong I.G., Kim J.K., Cho K.S., et al. Diffusion-weighted magnetic resonance imaging in patients with unilateral prostate cancer on extended prostate biopsy: predictive accuracy of laterality and implications for hemi-ablative therapy. J Urol 2010, 184(5):1963-1969.
32. Kitajima K., Kaji Y., Fukabori Y., et al. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010, 31(3):625-631.
33. Rosenkrantz A.B., Kopec M., Kong X., et al. Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging. J Magn Reson Imaging 2010, 31(6):1387-1394.
34. Oto A., Kayhan A., Jiang Y., et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010, 257(3):715-723.
35. Kim J.H., Kim J.K., Park B.W., et al. Apparent diffusion coefficient: prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging 2008, 28(5):1173-1179.
36. Tamada T., Sone T., Jo Y., et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008, 28(3):720-726.
37. Shi H., Kong X., Feng G., et al. Diffusion-weighted single-shot echo planar MR imaging of normal human prostate using different b values. J Huazhong Univ Sci Technolog Med Sci 2008, 28(6):737-740.
38. Ren J., Huan Y., Wang H., et al. Diffusion-weighted imaging in normal prostate and differential diagnosis of prostate diseases. Abdom Imaging 2008, 33(6):724-728.
39. Kozlowski P., Chang S.D., Goldenberg S.L. Diffusion-weighted MRI in prostate cancer: comparison between single-shot fast spin echo and echo planar imaging sequences. Magn Reson Imaging 2008, 26(1):72-76.
40. Pickles M.D., Gibbs P., Sreenivas M., et al. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging 2006, 23(2):130-134.
41. Gibbs P., Tozer D.J., Liney G.P., et al. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med 2001, 46(6):1054-1058.
42. Reischauer C., Wilm B.J., Froehlich J.M., et al. High-resolution diffusion tensor imaging of prostate cancer using a reduced FOV technique. Eur J Radiol 2011, 80(2):e34-e41.
43. Li C., Chen M., Li S., et al. Diffusion tensor imaging of prostate at 3.0 Tesla. Acta Radiol 2011, 52(7):813-817.
44. Kim C.K., Jang S.M., Park B.K. Diffusion tensor imaging of normal prostate at 3T: effect of number of diffusion-encoding directions on quantitation and image quality. Br J Radiol 2012, 85(1015):e279-e283.
45. Kozlowski P., Chang S.D., Meng R., et al. Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T: quantitative correlation with biopsy. Magn Reson Imaging 2010, 28(5):621-628.
46. Xu J., Humphrey P.A., Kibel A.S., et al. Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med 2009, 61(4):842-850.
47. Gurses B., Kabakci N., Kovanlikaya A., et al. Diffusion tensor imaging of the normal prostate at 3 Tesla. Eur Radiol 2008, 18(4):716-721.
48. Manenti G., Carlani M., Mancino S., et al. Diffusion tensor magnetic resonance imaging of prostate cancer. Invest Radiol 2007, 42(6):412-419.
49. Gibbs P., Pickles M.D., Turnbull L.W. Repeatability of echo-planar-based diffusion measurements of the human prostate at 3 T. Magn Reson Imaging 2007, 25(10):1423-1429.
50. Sinha S., Sinha U. In vivo diffusion tensor imaging of the human prostate. Magn Reson Med 2004, 52(3):530-537.
51. Gibbs P., Pickles M.D., Turnbull L.W. Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol 2006, 41(2):185-188.
52. Dopfert J., Lemke A., Weidner A., et al. Investigation of prostate cancer using diffusion-weighted intravoxel incoherent motion imaging. Magn Reson Imaging 2011, 29(8):1053-1058.
53. Pang Y., Turkbey B., Bernardo M., et al. Intravoxel incoherent motion MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations. Magn Reson Med 2012, 10.1002/mrm.24277.
54. Nagarajan R., Margolis D., Raman S., et al. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol 2012, 2012:374805.
55. Hambrock T., Hoeks C., Hulsbergen-van de Kaa C., et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012, 61(1):177-184.
56. Bittencourt L.K., Barentsz J.O., de Miranda L.C., et al. Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol 2012, 22(2):468-475.
57. Yamamura J., Salomon G., Buchert R., et al. Magnetic resonance imaging of prostate cancer: diffusion-weighted imaging in comparison with sextant biopsy. J Comput Assist Tomogr 2011, 35(2):223-228.
58. Verma S., Rajesh A., Morales H., et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 2011, 196(2):374-381.
59. Turkbey B., Shah V.P., Pang Y., et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?. Radiology 2011, 258(2):488-495.
60. Oto A., Yang C., Kayhan A., et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 2011, 197(6):1382-1390.
61. Itou Y., Nakanishi K., Narumi Y., et al. Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?. J Magn Reson Imaging 2011, 33(1):167-172.
62. Hambrock T., Somford D.M., Huisman H.J., et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and gleason grade in peripheral zone prostate cancer. Radiology 2011, 259(2):453-461.
63. Woodfield C.A., Tung G.A., Grand D.J., et al. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010, 194(4):W316-W322.
64. deSouza N.M., Riches S.F., Vanas N.J., et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008, 63(7):774-782.
65. Langer D.L., van der Kwast T.H., Evans A.J., et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008, 249(3):900-908.
66. Somford D.M., Hambrock T., Hulsbergen-van de Kaa C.A., et al. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score
67. Morgan V.A., Riches S.F., Thomas K., et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 2011, 84(997):31-37.
68. van As N.J., de Souza N.M., Riches S.F., et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2009, 56(6):981-987.
69. Nemoto K., Tateishi T., Ishidate T. Changes in diffusion-weighted images for visualizing prostate cancer during antiandrogen therapy: preliminary results. Urol Int 2010, 85(4):421-426.
70. Song I., Kim C.K., Park B.K., et al. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol 2010, 194(6):W477-W482.
71. Chen J., Daniel B.L., Diederich C.J., et al. Monitoring prostate thermal therapy with diffusion-weighted MRI. Magn Reson Med 2008, 59(6):1365-1372.
72. Iwazawa J., Mitani T., Sassa S., et al. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging?. Diagn Interv Radiol 2011, 17(3):243-248.
73. Langer D.L., van der Kwast T.H., Evans A.J., et al. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009, 30(2):327-334.
74. Tamada T., Sone T., Higashi H., et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol 2011, 197(3):664-670.
75. Tanimoto A., Nakashima J., Kohno H., et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007, 25(1):146-152.
76. Akin O., Gultekin D.H., Vargas H.A., et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 2011, 21(9):1970-1978.
77. Tamada T., Sone T., Jo Y., et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. AJR Am J Roentgenol 2011, 197(2):408-414.
78. Abou-El-Ghar M.E., El-Assmy A., Refaie H.F., et al. Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology 2009, 251(2):415-421.
79. El-Assmy A., Abou-El-Ghar M.E., Refaie H.F., et al. Diffusion-weighted MR imaging in diagnosis of superficial and invasive urinary bladder carcinoma: a preliminary prospective study. SciWorld J 2008, 8:364-370.
80. El-Assmy A., Abou-El-Ghar M.E., Mosbah A., et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol 2009, 19(7):1575-1581.
81. Watanabe H., Kanematsu M., Kondo H., et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value?. AJR Am J Roentgenol 2009, 192(5):1361-1366.
82. Giannarini G., Petralia G., Thoeny H.C. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 2012, 61(2):326-340.
83. Takeuchi M., Sasaki S., Ito M., et al. Urinary bladder cancer: diffusion-weighted MR imaging-accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009, 251(1):112-121.
84. Shinya S., Sasaki T., Nakagawa Y., et al. The efficacy of diffusion-weighted imaging for the detection of colorectal cancer. Hepatogastroenterology 2009, 56(89):128-132.
85. Hein P.A., Kremser C., Judmaier W., et al. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 2003, 45(3):214-222.
86. Barbaro B., Vitale R., Valentini V., et al. Diffusion-weighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012, 83(2):594-599.
87. Kim S.H., Lee J.M., Hong S.H., et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 2009, 253(1):116-125.
88. Kim S.H., Lee J.Y., Lee J.M., et al. Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Eur Radiol 2011, 21(5):987-995.
89. Jung S.H., Heo S.H., Kim J.W., et al. Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging. J Magn Reson Imaging 2012, 35(1):110-116.
90. Lambrecht M., Vandecaveye V., De Keyzer F., et al. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys 2012, 82(2):863-870.
91. Dzik-Jurasz A., Domenig C., George M., et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002, 360(9329):307-308.
92. Curvo-Semedo L., Lambregts D.M., Maas M., et al. Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy-conventional MR volumetry versus diffusion-weighted MR imaging. Radiology 2011, 260(3):734-743.
93. Carbone S.F., Pirtoli L., Ricci V., et al. Assessment of response to chemoradiation therapy in rectal cancer using MR volumetry based on diffusion-weighted data sets: a preliminary report. Radiol Med 2012, [Epub ahead of print].
94. Mir N., Sohaib S.A., Collins D., et al. Fusion of high b-value diffusion-weighted and T2-weighted MR images improves identification of lymph nodes in the pelvis. J Med Imaging Radiat Oncol 2010, 54(4):358-364.
95. Beer A.J., Eiber M., Souvatzoglou M., et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 2011, 13(2):352-361.
96. Budiharto T., Joniau S., Lerut E., et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011, 60(1):125-130.
97. Eiber M., Beer A.J., Holzapfel K., et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 2010, 45(1):15-23.
98. Thoeny H.C., Triantafyllou M., Birkhaeuser F.D., et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009, 55(4):761-769.
99. Pearce T., Philip S., Brown J., et al. Bone metastases from prostate, breast and multiple myeloma: differences in lesion conspicuity at short-tau inversion recovery and diffusion-weighted MRI. Br J Radiol 2012, 85(1016):1102-1106.
100. Gutzeit A., Doert A., Froehlich J.M., et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010, 39(4):333-343.
101. Lecouvet F.E., El Mouedden J., Collette L., et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?. Eur Urol 2012, 62(1):68-75.
102. Luboldt W., Kufer R., Blumstein N., et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 2008, 249(3):1017-1025.
103. Xu X., Ma L., Zhang J.S., et al. Feasibility of whole body diffusion weighted imaging in detecting bone metastasis on 3.0T MR scanner. Chin Med Sci J 2008, 23(3):151-157.
104. Messiou C., Collins D.J., Giles S., et al. Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. Eur Radiol 2011, 21(10):2169-2177.
105. Reischauer C., Froehlich J.M., Koh D.M., et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology 2010, 257(2):523-531.
106. Kim C.K., Park B.K., Han J.J., et al. Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results. J Comput Assist Tomogr 2007, 31(3):449-454.
107. Zelhof B., Pickles M., Liney G., et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2009, 103(7):883-888.
108. Kim C.K., Park B.K., Kim B. High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2. AJR Am J Roentgenol 2010, 194(1):W33-W37.
109. Reinsberg S.A., Payne G.S., Riches S.F., et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol 2007, 188(1):91-98.
110. Sato C., Naganawa S., Nakamura T., et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005, 21(3):258-262.